Stocks in play: Bausch Health Companies Inc.
And Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark) announced that RYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray) has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged six years and older. Bausch Health Companies Inc. shares T.BHC are trading down $0.20 at $9.43.
Read:
Highly Sought After Natural Ingredients Appearing in More Plant-Based Products Across North America
Fresher, Healthier Food Options Coming Soon to an Airplane Tray Near You
Airline Industry Wooing Back Customers with Enhanced, Healthier Menu Options
Vegetarian and Vegan Fliers Winning Important Battle Over In-Flight Menu Options
Mega Grocery Store Chains Listening to Customers’ Demands for Nutritious, Clean-Label Foods